Prokidney (PROK) Equity Average (2021 - 2026)
Prokidney (PROK) reported Equity Average of -$1.0 billion for Q1 2026, down 2.08% year-over-year from -$1.0 billion in Q1 2025, and down 0.78% on a QoQ basis from -$1.0 billion in Q4 2025.
Prokidney (PROK) has 6 years of Equity Average data on file, last reported at -$1.0 billion in Q1 2026.
- Quarterly Equity Average fell 2.08% year-over-year to -$1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 2.08% YoY) and the FY2025 annual result came in at -$1.0 billion, up 4.39% from the prior year.
- Equity Average retreated to -$1.0 billion in Q1 2026 per PROK's latest filing, from -$1.0 billion in the prior quarter.
- Across five years, Equity Average topped out at $23.5 million in Q1 2022 and bottomed at -$1.5 billion in Q2 2023.
- The 5-year median for Equity Average is -$1.0 billion (2025), against an average of -$932.2 million.
- The widest annual swing landed in 2022, when Equity Average jumped 67.95%; it then tumbled 11048.79% in 2023.
- Tracing PROK's Equity Average over 5 years: stood at -$1.1 billion in 2022, then fell by 0.14% to -$1.1 billion in 2023, then grew by 10.08% to -$987.3 million in 2024, then fell by 2.26% to -$1.0 billion in 2025, then slipped by 0.78% to -$1.0 billion in 2026.
- Per Business Quant, the three latest PROK Equity Average figures stand at -$1.0 billion (Q1 2026), -$1.0 billion (Q4 2025), and -$1.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Prokidney | 259.72 Mn | 1.55 Bn | - | -1.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.02 Bn |
| Dec 31, 2025 | -1.01 Bn |
| Sep 30, 2025 | -1.01 Bn |
| Jun 30, 2025 | -1.00 Bn |
| Mar 31, 2025 | -996.75 Mn |
| Dec 31, 2024 | -987.33 Mn |
| Sep 30, 2024 | -976.04 Mn |
| Jun 30, 2024 | -1.03 Bn |
| Mar 31, 2024 | -1.10 Bn |
| Dec 31, 2023 | -1.10 Bn |
| Sep 30, 2023 | -1.21 Bn |
| Jun 30, 2023 | -1.46 Bn |
| Mar 31, 2023 | -1.35 Bn |
| Dec 31, 2022 | -1.10 Bn |
| Sep 30, 2022 | -544.89 Mn |
| Jun 30, 2022 | 13.35 Mn |
| Mar 31, 2022 | 23.54 Mn |
| Dec 31, 2021 | 18.66 Mn |
| Sep 30, 2021 | 13.15 Mn |
| Jun 30, 2021 | 7.95 Mn |